John L. Villano, MD, PhD
John L. Villano, MD, PhD
- Director, Clinical Neuro-Oncology Research Program
- Medical Director, Precision Medicine Clinic
About
John L. Villano specializes in the treatment of brain cancers. He will advance UK HealthCare's Clinical Neuro-Oncology Research Program, serving as its director. UK HealthCare has a history of being a world-class neuro-oncology program, and he will help carry this tradition into the future.
Previously, Dr. Villano served as the director of medical neuro-oncology at the University of Illinois Medical Center. He earned a medical degree and doctor of philosophy at the University of Texas Southwestern Medical School at Dallas and trained in neurology at the University of Michigan. He also completed a fellowship in hematology/oncology at the University of Chicago. He is a former American Society of Clinical Oncology track leader for CNS tumors. Currently, he is on the board of the Central Brain Tumor Registry US. He is also a member of the Neuro-Oncology Committee in the cooperative group ALLIANCE and a Society of Neuro-Oncology committee member.
Faculty Rank
- Medical Director, Precision Medicine Clinic
- Professor of Medicine
Training & Education
Degree
Residency
Fellowship
Certifications and Special Training
Research
Research Focus
Clinical Trials involved in Neuro-Oncology and in lung cancer. I am also involved in collaborated with the investigators at Kentucky Cancer Registry (KCR) and at Central Brain Tumor Registry of the United States (CBTRUS) to perform descriptive epidemiology studies. We have worked on topics that are less known or investigated, where application of clinical knowledge assists in interpretation of epidemiology data.
Programs
Translational OncologyCollege & Department
Contact Information
Publications
- Four-jointed is required for intermediate growth in the proximal-distal axis in Drosophila.Villano, J.L. and Katz, F.N. (1995) Development. 121:2767-77.
- NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality.Stupp, R., Wong, E.T., Kanner, A.A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E.D., Taillibert, S., Liebermann, F., Dbalý, V., Ram, Z., Villano, J.L., Rainov, N., Weinberg, U., Schiff, D., Kunschner, L., Raizer, J., Honnorat, J., Sloan, A., Malkin, M., Landolfi, J.C., Payer, F., Mehdorn, M., Weil, R.J., Pannullo, S.C., Westphal, M., Smrcka, M., Chin, L., Kostron, H., Hofer, S., Bruce, J., Cosgrove, R., Paleologous, N., Palti, J., Gutin, P.H. (2012) Eur J Cancer. 48(14):2192-202
- Incidence of Brain Metastasis at Initial Presentation of Lung Cancer.Villano, J.L., Durbin, E.B., Normandeau, C., Thakkar, J.P., Moirangthem, V., Davis, F.G. (2014) Neuro-Oncol. 17(1):122-8
- Epidemiology of Meningiomas Post Public Law 107-206 - The Benign Brain Tumor Cancer Registries Amendment Act.Dolecek, T.A., Dressler, E.V., Thakkar, J.P., Liu, M., Al-Qaisi, A., Villano, J.L. (2015) Cancer. 121(14):2400-10
- Incidence of CNS tumors in Appalachian children.Huang, B., Luo, A., Durbin, E.B., Lycan, E., Tucker, T., Chen, Q., Horbinski, C., Villano, J.L. (2017) J Neuro-Oncol. Mar 11. [Epub ahead of print].